Related Experiment Video
Updated: Aug 10, 2026
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
[Effects of STAT3 antisense oligodeoxynucleotides on apoptosis and proliferation of mouse melanoma cell line B16]
Gu-Sheng Tang1, Jian-Ming Cai, Jin Ni
1Department of Radiomedicine, The Second Military Medical University, Shanghai 200433, P.R. China.
Background & Objective:
STAT3 protein has been found constitutively activated in a wide variety of human tumor tissues and cell lines. It may be involved in tumorigenesis and development. This study was to observe the activation of STAT3 protein in mouse melanoma cell line B16, human liver cancer cell lines SMMC-7721 and HepG-2, human lung cancer cell line A549, and human cervical cancer cell line HeLa, and to investigate the effects of STAT3 antisense oligodeoxynucleotides (ASODN) on proliferation and apoptosis of B16 cells.
Methods:
B16 cells were transfected with STAT3 ASODN or STAT3 sense oligodeoxynucleotides (STAT3 SODN), respectively. The expression and phosphorylation levels of STAT3 protein in all the tumor cells were measured by Western blot. The proliferation of B16 cells was detected by MTT assay. Cell apoptosis was determined by Hoechst33258 staining and Annexin V/PI using flow cytometry.
Results:
STAT3 was highly expressed and phosphorylated in all the tumor cells. Transfection of STAT3 ASODN suppressed the expression and phosphorylation levels of STAT3 protein in B16 cells. Forty-eight hours after transfection, the proliferation of B16 cells was inhibited the higher the concentration (0-200 nmol/L) of STAT3 ASODN was, the heavier the inhibition was (P<0.01); when transfected with STAT3 SODN over 250 nmol/L, the proliferation of B16 cells was also inhibited (P<0.05). Inhibitory effects appeared 24 h later after transfection of STAT3 ASODN, and became more obvious 48 h later (P<0.01). The early apoptosis rate was significantly higher in 400, 800, 2,000 nmol/L STAT3 ASODN groups and 2,000 nmol/L STAT3 SODN group than in blank control group (8.22%, 9.99%, 16.97%, and 13.31% vs. 5.52%, P<0.01); no significant difference was found among 400 and 800 nmol/L STAT3 SODN groups and blank control group (5.87%, 5.36% and 5.52%, P>0.05).
Conclusions:
STAT3 is highly expressed and activated in all the tumor cells detected. STAT3 ASODN can abrogate the activity of STAT3 protein, inhibit proliferation and induce apoptosis of B16 cells, which support that STAT3 may be a potential molecular target for tumor therapy.
Insights
STAT3 protein is highly active in various cancers. STAT3 antisense oligodeoxynucleotides (ASODN) effectively inhibit STAT3 activity, suppress tumor cell proliferation, and induce apoptosis in melanoma cells, indicating its potential as a therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Context:
- Constitutive activation of STAT3 protein is observed in numerous human tumor tissues and cell lines.
- STAT3 signaling pathways are implicated in tumorigenesis and cancer progression.
Purpose:
- To investigate STAT3 protein activation in B16 melanoma, SMMC-7721 and HepG-2 liver, A549 lung, and HeLa cervical cancer cells.
- To evaluate the effects of STAT3 antisense oligodeoxynucleotides (ASODN) on B16 cell proliferation and apoptosis.
Summary:
- STAT3 protein was highly expressed and phosphorylated across all tested cancer cell lines.
- Transfection with STAT3 ASODN significantly reduced STAT3 expression and phosphorylation in B16 cells.
- STAT3 ASODN treatment inhibited B16 cell proliferation in a dose-dependent manner and induced significant apoptosis.
Impact:
- STAT3 ASODN effectively abrogates STAT3 activity, leading to reduced proliferation and increased apoptosis in B16 melanoma cells.
- These findings highlight STAT3 as a potential molecular target for developing novel cancer therapies.
